タダラフィルの世界市場レポート 2025年

タダラフィルの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.46％で88億7,000万米ドルに成長します。予測期間中に予想される成長の原動力は、勃起不全の有病率の上昇、生活習慣病治療薬に対する需要の高まり、肺動脈性肺高血圧症（PAH）症例の増加、最新のヘルスケアソリューションの採用拡大、可処分所得の上昇です。この期間に予想される主な動向には、デジタルヘルスの統合、革新的な薬剤処方、医薬品の進歩、ドラッグデリバリーシステムの改善、医療技術の進歩などがあります。

勃起不全の有病率の上昇は、今後数年間のタダラフィル市場の成長を牽引すると予想されます。勃起不全（ED）とは、満足な性行為を行うのに十分な勃起が持続的に得られない、または維持できないことを特徴とする状態です。EDの有病率増加の要因としては、人口の高齢化、慢性的な健康状態、不健康なライフスタイルの選択、心理的ストレス、特定の薬剤の副作用などが挙げられます。タダラフィルは、陰茎の血管の平滑筋を弛緩させ、血流を改善し、性的刺激時に勃起を可能にすることにより、EDに対処します。例えば、国立医学図書館の2024年2月の報告によると、IIEF-5スコアで測定されるEDの有病率は、一般人口で24.2％であり、65歳以上では著しく高く、65～74歳で48.0％、75歳以上で52.2％が罹患しています。この有病率の増加が、タダラフィル市場の拡大に拍車をかけています。

タダラフィル市場の主要企業は、治療効果を高め、患者のコンプライアンスを向上させ、勃起不全と肺動脈性肺高血圧症の管理において市場での存在感を強めるために、併用療法などの革新的な製剤を優先しています。併用療法は、治療成績を向上させ、病態の複数の側面に対処し、治療効果を高めるために、2種類以上の薬剤を同時に使用するものです。例えば、2024年3月、ジョンソン・エンド・ジョンソンは、エンドセリン受容体拮抗薬（ERA）であるマキテンタンとホスホジエステラーゼ5（PDE5）阻害薬であるタダラフィルを組み合わせた単一錠剤療法であるOPSYNVIのFDA承認を発表しました。OPSYNVIは、WHO機能分類II～III度の成人肺動脈性肺高血圧症（PAH）の慢性管理用に設計されており、治療歴のない患者にも、ERA、PDE5阻害薬、またはその両方ですでに安定している患者にも適しています。この革新的な治療法は、これまでmacitentanとタダラフィルを別々に服用していた患者の治療レジメンを簡素化します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界タダラフィルPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のタダラフィル市場：成長率分析
• 世界のタダラフィル市場の実績：規模と成長, 2019-2024
• 世界のタダラフィル市場の予測：規模と成長, 2024-2029, 2034F
• 世界タダラフィル総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のタダラフィル市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 経口懸濁液
• 世界のタダラフィル市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のタダラフィル市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 勃起不全
• 肺動脈高血圧
• 良性前立腺肥大症
• 世界のタダラフィル市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2.5mg錠
• 5mg錠
• 10mg錠
• 20mg錠
• 世界のタダラフィル市場経口懸濁液の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2.5 mg/5 mL経口懸濁液
• 10 mg/5 mL経口懸濁液
• カスタム投与経口懸濁液

第7章 地域別・国別分析

• 世界のタダラフィル市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のタダラフィル市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• タダラフィル市場：競合情勢
• タダラフィル市場：企業プロファイル
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Dr. Reddy's Laboratories Limited
• Lupin Limited
• Glenmark Pharmaceuticals Limited
• Torrent Pharmaceuticals Limited
• Jubilant Pharma Limited
• Jiangsu Lianhuan Pharmaceutical Co. Ltd.
• Alembic Pharmaceuticals Limited
• Polpharma SA
• SMS Pharmaceuticals Limited
• Camber Pharmaceuticals Inc.
• Century Pharmaceuticals Limited
• Rakshit Drugs Private Limited
• Ami Lifesciences Private Limited
• Hangzhou Longshine Bio-Tech Co. Ltd.
• Dolphin Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• タダラフィル市場2029：新たな機会を提供する国
• タダラフィル市場2029：新たな機会を提供するセグメント
• タダラフィル市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor primarily used to treat erectile dysfunction and pulmonary arterial hypertension. It functions by relaxing blood vessels, enhancing blood flow to specific areas, and effectively managing these conditions.

Tadalafil is available mainly in two forms, tablets and oral suspensions. Tadalafil tablets, being solid oral medications, offer accurate dosing, are user-friendly, and are widely prescribed for erectile dysfunction due to their effectiveness and ease of use. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. It is utilized for various purposes, including the treatment of erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.

The tadalafil market research report is one of a series of new reports from The Business Research Company that provides tadalafil market statistics, including the tadalafil industry global market size, regional shares, competitors with the tadalafil market share, detailed tadalafil market segments, market trends, and opportunities, and any further data you may need to thrive in the tadalafil industry. This tadalafil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tadalafil market size has grown rapidly in recent years. It will grow from $4.92 billion in 2024 to $5.55 billion in 2025 at a compound annual growth rate (CAGR) of 12.83%. The growth during the historical period can be attributed to increasing awareness of men's health, the rising usage of medications, the expanding tadalafil market, growing healthcare expenditures, and an aging population.

The tadalafil market size is expected to see rapid growth in the next few years. It will grow to $8.87 billion in 2029 at a compound annual growth rate (CAGR) of 12.46%. The anticipated growth in the forecast period is driven by a higher prevalence of erectile dysfunction, a growing demand for lifestyle medications, an increase in pulmonary arterial hypertension (PAH) cases, greater adoption of modern healthcare solutions, and rising disposable incomes. Key trends expected during this period include the integration of digital health, innovative drug formulations, advancements in pharmaceuticals, improved drug delivery systems, and progress in medical technology.

The rising prevalence of erectile dysfunction is expected to drive the growth of the tadalafil market in the coming years. Erectile dysfunction (ED) is a condition characterized by the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Factors contributing to the increasing prevalence of ED include an aging population, chronic health conditions, unhealthy lifestyle choices, psychological stress, and the side effects of certain medications. Tadalafil addresses ED by relaxing smooth muscles in the blood vessels of the penis, improving blood flow, and enabling an erection during sexual stimulation. For example, a February 2024 report from the National Library of Medicine revealed that the prevalence of ED, as measured by IIEF-5 scores, is 24.2% in the general population, with significantly higher rates among individuals aged 65 and older, affecting 48.0% of those aged 65-74 and 52.2% of those 75 and older. This growing prevalence is fueling the expansion of the tadalafil market.

Leading companies in the tadalafil market are prioritizing innovative formulations, such as combination therapies, to boost treatment efficacy, enhance patient compliance, and strengthen their market presence in managing erectile dysfunction and pulmonary arterial hypertension. Combination therapy involves the simultaneous use of two or more medications to improve therapeutic outcomes, address multiple aspects of a condition, and enhance treatment effectiveness. For instance, in March 2024, Johnson & Johnson announced FDA approval for OPSYNVI, a single-tablet therapy combining macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Designed for the chronic management of pulmonary arterial hypertension (PAH) in adults with WHO functional class II-III, OPSYNVI is suitable for both treatment-naive patients and those already stabilized on ERA, PDE5 inhibitors, or both. This innovative therapy simplifies treatment regimens for patients previously taking macitentan and tadalafil separately.

In February 2024, Zuellig Pharma Holdings Ltd., a Singapore-based healthcare solutions provider, acquired Cialis (Tadalafil) and Alimta (Pemetrexed) from Eli Lilly and Company for an undisclosed sum. The acquisition allows Zuellig Pharma to expand its pharmaceutical portfolio, strengthen its market presence, and meet the growing demand for treatments addressing erectile dysfunction (Cialis) and cancer (Alimta) within its operational regions. Eli Lilly and Company, a US-based pharmaceutical firm, produces tadalafil-based treatments for erectile dysfunction and pulmonary arterial hypertension.

Major players in the tadalafil market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Jubilant Pharma Limited, Jiangsu Lianhuan Pharmaceutical Co. Ltd., Alembic Pharmaceuticals Limited, Polpharma SA, SMS Pharmaceuticals Limited, Camber Pharmaceuticals Inc., Century Pharmaceuticals Limited, Rakshit Drugs Private Limited, Ami Lifesciences Private Limited, Hangzhou Longshine Bio-Tech Co. Ltd., Dolphin Pharmaceuticals.

North America was the largest region in the tadalafil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tadalafil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tadalafil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tadalafil market consists of sales of injectable formulations, extended-release formulations, and topical formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tadalafil Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tadalafil market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tadalafil ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tadalafil market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Tablets; Oral Suspensions
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By Application: Erectile Dysfunction; Pulmonary Arterial Hypertension; Benign Prostatic Hyperplasia
• Subsegments:
• 1) By Tablets: 2.5 mg Tablets; 5 mg Tablets; 10 mg Tablets; 20 mg Tablets
• 2) By Oral Suspensions: 2.5 mg/5 mL Oral Suspension; 10 mg/5 mL Oral Suspension; Custom Dosing Oral Suspensions
• Companies Mentioned: Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Limited; Cipla Limited; Aurobindo Pharma Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tadalafil Market Characteristics

3. Tadalafil Market Trends And Strategies

4. Tadalafil Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tadalafil Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tadalafil PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tadalafil Market Growth Rate Analysis
• 5.4. Global Tadalafil Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tadalafil Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tadalafil Total Addressable Market (TAM)

6. Tadalafil Market Segmentation

• 6.1. Global Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Oral Suspensions
• 6.2. Global Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erectile Dysfunction
• Pulmonary Arterial Hypertension
• Benign Prostatic Hyperplasia
• 6.4. Global Tadalafil Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 2.5 mg Tablets
• 5 mg Tablets
• 10 mg Tablets
• 20 mg Tablets
• 6.5. Global Tadalafil Market, Sub-Segmentation Of Oral Suspensions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 2.5 mg/5 mL Oral Suspension
• 10 mg/5 mL Oral Suspension
• Custom Dosing Oral Suspensions

7. Tadalafil Market Regional And Country Analysis

• 7.1. Global Tadalafil Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tadalafil Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tadalafil Market

• 8.1. Asia-Pacific Tadalafil Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tadalafil Market

• 9.1. China Tadalafil Market Overview
• 9.2. China Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tadalafil Market

• 10.1. India Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tadalafil Market

• 11.1. Japan Tadalafil Market Overview
• 11.2. Japan Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tadalafil Market

• 12.1. Australia Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tadalafil Market

• 13.1. Indonesia Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tadalafil Market

• 14.1. South Korea Tadalafil Market Overview
• 14.2. South Korea Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tadalafil Market

• 15.1. Western Europe Tadalafil Market Overview
• 15.2. Western Europe Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tadalafil Market

• 16.1. UK Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tadalafil Market

• 17.1. Germany Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tadalafil Market

• 18.1. France Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tadalafil Market

• 19.1. Italy Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tadalafil Market

• 20.1. Spain Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tadalafil Market

• 21.1. Eastern Europe Tadalafil Market Overview
• 21.2. Eastern Europe Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tadalafil Market

• 22.1. Russia Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tadalafil Market

• 23.1. North America Tadalafil Market Overview
• 23.2. North America Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tadalafil Market

• 24.1. USA Tadalafil Market Overview
• 24.2. USA Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tadalafil Market

• 25.1. Canada Tadalafil Market Overview
• 25.2. Canada Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tadalafil Market

• 26.1. South America Tadalafil Market Overview
• 26.2. South America Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tadalafil Market

• 27.1. Brazil Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tadalafil Market

• 28.1. Middle East Tadalafil Market Overview
• 28.2. Middle East Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tadalafil Market

• 29.1. Africa Tadalafil Market Overview
• 29.2. Africa Tadalafil Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tadalafil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tadalafil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tadalafil Market Competitive Landscape And Company Profiles

• 30.1. Tadalafil Market Competitive Landscape
• 30.2. Tadalafil Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

31. Tadalafil Market Other Major And Innovative Companies

• 31.1. Dr. Reddy's Laboratories Limited
• 31.2. Lupin Limited
• 31.3. Glenmark Pharmaceuticals Limited
• 31.4. Torrent Pharmaceuticals Limited
• 31.5. Jubilant Pharma Limited
• 31.6. Jiangsu Lianhuan Pharmaceutical Co. Ltd.
• 31.7. Alembic Pharmaceuticals Limited
• 31.8. Polpharma SA
• 31.9. SMS Pharmaceuticals Limited
• 31.10. Camber Pharmaceuticals Inc.
• 31.11. Century Pharmaceuticals Limited
• 31.12. Rakshit Drugs Private Limited
• 31.13. Ami Lifesciences Private Limited
• 31.14. Hangzhou Longshine Bio-Tech Co. Ltd.
• 31.15. Dolphin Pharmaceuticals

32. Global Tadalafil Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tadalafil Market

34. Recent Developments In The Tadalafil Market

35. Tadalafil Market High Potential Countries, Segments and Strategies

• 35.1 Tadalafil Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tadalafil Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tadalafil Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer